28 results on '"Pichler, Renate"'
Search Results
2. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
3. Clinico-pathological features influencing the prognostic role of Body Mass Index in patients with advanced Renal Cell Carcinoma treated by immuno-oncology combinations (ARON-1)
4. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
5. Rare, but severe: Delayed genitoscrotal necrosis after HIPEC with Mitomycin-C
6. Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
7. Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up
8. Rare, but Severe: Vasculitis and Checkpoint Inhibitors
9. Drug-Drug Interactions in Prostate Cancer Treatment
10. Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
11. Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study
12. Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol 2019;75:853–60
13. Therapeutic rationale of targeting BCG and immune checkpoints in non–muscle-invasive bladder cancer: Is this the Future?
14. Re: Peter K.-F. Chiu, Chi-Fai Ng, Axel Semjonow, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol 2019;75:558–61
15. Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report
16. Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients
17. A rare case of a 123I-MIBG SPECT/CT positive, but 68Ga-DOTA-TOC PET/CT negative pheochromocytoma of the bladder
18. Renal rupture – Not what it seems
19. Effect of Urinary Cytology for Detecting Recurrence in Remnant Urothelium After Radical Cystectomy: Insights From a 10-year Cytology Database
20. Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776–87
21. Pelvic Lymph Node Staging by Combined 18 F-FDG-PET/CT Imaging in Bladder Cancer Prior to Radical Cystectomy
22. High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: A 10-year single-center experience
23. Paratesticular Metastasis of a Clear-Cell Renal-Cell Carcinoma With Renal Vein Thrombus Mimicking Primary Testicular Cancer
24. Long-Term Follow-Up of a Primary Teratoma With Somatic-Type Malignancy Within the Thyroid Gland Mimicking Thyroid Carcinoma
25. Organ Preservation Technique Without Ischemia in Patients With Testicular Tumor
26. Gender-related Fetal Development of the Internal Urethral Sphincter
27. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
28. Postchemotherapy Laparoscopic Retroperitoneal Lymph Node Dissection for Low-volume, Stage II, Nonseminomatous Germ Cell Tumor: First 100 Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.